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Editorial on the Research Topic
Cancer Stem Cells in Endocrine Tumors
Endocrine tumors (ETs) include both benign and malignant diseases, originated from the boosted
proliferation capacity of the hormone-producing glands of the endocrine system, and are
characterized by a high degree of complexity and cellular heterogeneity. In this context, a crucial
role in ET initiation and progression seems to be played by cancer cells endowed with stem cell
properties, called cancer stem cells (CSCs), only recently identified in ETs, which presence is often
associated with chemoresistance and metastatic potential. The aim of this Research Topic is to
summarize all the findings regarding the role of CSCs in ETs, the peculiar properties of cancer
versus healthy stem cells in different endocrine organs, highlighting the progress made in this
research field, as well as the current contradictions. Recent findings have demonstrated that CSCs
could arise from normal stem cells, upon acquisition of (epi)genetic hits, or by de-differentiation of
progenitor/differentiated cells. For this reason, a better study of CSCs’ healthy counterpart could
lead to a better understanding of cancer cell biology and treatment.
In this context, Mariniello et al. study the role of healthy stem cells in the development and self-
renewal of endocrine organs (pituitary, adrenal gland, thyroids, parathyroids, gonads, pancreas), as
well as their functions in regenerative medicine, highlighting how alterations in the mechanisms
acting in stem cells may lead to development of endocrine cancer.
An example of the biological mechanisms underlying transformation of normal to CSCs is
reported in the review by Veschi, Verona, Lo Iacono et al. Indeed, despite several thyroid
tumorigenesis models have been recently proposed, the thyroid CSC genetic mutation model has
been reported to elucidate the molecular mechanisms underlying the distinct thyroid cancer (TC)
histopathology and clinical behavior (1). In this review the authors examined the principal pathways
and epigenetic alterations sustaining TCSC survival and the complex crosstalk between TCSCs and
the tumor microenvironment cell populations, to define more effective therapeutic strategies, as
immunotherapy and epigenetic drugs.
In line with the model describing CSCs as derived from healthy stem cells, the review article
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the isolation of CSCs in neuroblastoma (NB), the most common
extracranial neoplasm in children. Targeting CSC subset may
overcome NB recurrence and resistance to therapy. Of note, the
authors discussed the mesenchymal (S-type) and adrenergic
(N-type) phenotypes of NB-CSCs with tumor-initiating
properties and their epigenetic traits, and explored the most
recent therapeutic applications and strategies for CSCs targeting.
A tumor type that shares the same cell of origin as NB is
pheochromocytoma, which originates from the chromaffin cells
located in the adrenal medulla (pheochromocytoma-PCC) or in
parasympathetic paraganglia (paraganglioma-PGL). In their
review, Scriba et al. summarize where we stand with the
identification of normal chromaffin stem cells (SCs), and of
putative CSCs in PCC/PGL. Although the precise role of these
cells, characterized by the expression of nestin, Oct4, Nanog, and
Sox2, is still unclear, their involvement in the maintenance of stem
cell niche, as well as in tumorigenesis is discussed, with particular
focus on the development of targeted therapies for the treatment of
metastatic tumors.
The pioneering work of Hugo Vankelecom set the stage for
the identification of SCs in the pituitary gland, having roles in
embryogenesis and in adult tissues, as well as in pituitary tumors
(2, 3). Pituitary SCs and somatotroph cells express the proto-
oncogene RET, which plays a role in cell survival. The study
by Pradilla Dieste et al. systematically tackled the expression of
the RET co-receptors GFRa 1,2,3, and 4 across the lobes and
individual cell types of both rat and human pituitaries. Following
extensive stainings, they could demonstrate that GFRa co-
receptors are expressed in pituitary SCs at the niche in both
species. The differential distribution of GFRas is novel and
provocative, indicating that some co-receptors' expression is
retained in differentiated cells. This study suggests a potential
involvement of GFRa co-receptors in maintaining stemness of
the pituitary SC niche, and in directing proper lineage
differentiation of adenopituitary cells, further supporting a role
for RET/GFRa signaling in pituitary plasticity.
Although the isolation and characterization of cancer cells
endowed with stemness properties has been achieved in several
malignancies, the identification of tumor stem cells is not always
child’s play. In their reviewMantovani et al. summarize the current
knowledge about the tumor stem cells (TSCs) from pituitary
tumors, a relatively recent research line, which is born following
the identification of normal stem cells in the adult pituitary gland
(4), with the first study describing a population of cells in pituitary
tumors presenting CSC properties published by Xu et al. in 2009
(5). However, contrasting and not fully convincing data have been
reported about the in vivo tumorigenic capacity of TSCs in mouse
models, and the lack of reproducible data on long-term and serial
in vivo growth. Another important feature of TSCs is the therapy
resistance, as observed in many other tumor models. Even in this
context, different studies have highlighted that pituitary TSCs are
sensitive to drugs currently used in clinical setting, thus
questioning role of these cells in driving the pharmacological
resistance observed in pituitary tumor patients (6, 7). On the
same page regarding the clinical implication of pituitary adenoma
stem cells, and the controversial findings obtained in their isolationFrontiers in Endocrinology | www.frontiersin.org 2and in vitro/in vivo experimentation is the group of Würth et al.,
who analyzed in depth the experimental settings used to isolate
and characterize the pituitary adenoma stem cell population, with
a focus on their specific activated signaling pathways associated
with the regulation of stemness and EMT (i.e. Notch, Shh, Wnt
and Hippo). These studies emphasize that, although consistent
data are available regarding the existence of pituitary adenoma
stem cells, there is still an urgent need to address some unsolved
questions with future studies, to design effective therapeutic
protocols for the treatment of chemoresistant/invasive pituitary
tumors. Cancer stemness has been often associated with the
acquisition of mesenchymal traits, driven by a process known as
epithelial-to-mesenchymal transition (EMT) that sustains cancer
cell progression, which has been observed in few endocrine cancers
including pancreatic, prostate, thyroid, and pituitary cancers (8).
In their review, Bhattacharya and Scimè analyze in detail the main
metabolic processes involved in EMT, such as the shift in glucose
utilization towards aerobic glycolysis and the changes in lipid
metabolism, typical stem cell-like feature that characterize these
transitions in pancreatic, prostate, thyroid, and pituitary cancers.
Interestingly, acquisition of stem-like properties is not restricted
to cancer cell only, but this process has also been described
for fibroblast (cancer-associated fibroblasts) and adipose cells
(cancer-associated adipose cells) in the context of tumor
microenvironment (9). These findings highlight the metabolic
plasticity in endocrine tumors of the cancer cells and of the
tumor microenvironment components which can reciprocally
induce re-acquisition of stem-like properties supporting
cancer progression.
All these findings highlight the controversial origin and the key
role of CSCs in different steps of ETs’ progression, thus
underlining the clinical importance of their study for the
development of innovative target therapies, to improve the
quality of life of ETs’ patients. Nonetheless, further studies are
urgently needed to solve the existing controversial findings, and to
develop novel and reliable in vitro/in vivo models to increase the
scientific soundness and reproducibility of the obtained results.AUTHOR CONTRIBUTIONS
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